Everstone healthcare platform Everlife names Raman Gandotra as CEO

Everlife CEO Raman Gandotra

Private equity firm Everstone-led pan-Asian healthcare platform Everlife has appointed Raman Gandotra as its Chief Executive Officer (CEO).

Gandotra, who brings with him over 25 years of experience, will be based out of Singapore, and will lead the platform through its next stage of growth, Everstone said in a statement. The platform will further strengthen the company’s position in core markets and priority segments through acquisitions and realising synergies across portfolio companies, it added.

“Raman is very well-positioned to take the helm of Everlife, given his experience, skills and his action-oriented leadership style. The Board and I have strong confidence in his ability to identify and deliver on opportunities to drive growth, strengthen our operational cadence and cement our position in the region as a leader in our space,” said Arjun Oberoi, Vice Chairman of the Board, Everlife and Managing Director, Everstone Capital.

Prior to joining Everlife, Gandotra was leading the India and South-East Asia business of British medical technology company Smith & Nephew. There he was responsible for customer segmentation and targeting, driving operational excellence initiatives across countries, and for creating effective engagement strategies with distribution partners.

He has also held leadership roles in India and South-East Asia at Baxter and Allergan.

“Everlife has already emerged as a leader in the laboratory, medical equipment and devices space in Asia. I look forward to leading the next phase of Everlife’s journey through its expansion in new geographies and product segments and adopting new tools and technologies to bring superior value to our customers,” Gandotra said.

Established in 2017, Everlife’s investments include CPC Diagnostics, an India-based manufacturer and marketer of in-vitro diagnostic products; Malaysia-based Chemopharm Group, a provider of products and solutions to laboratory, research and medical facilities in South-East Asia; Indonesia’s DV Medika Group; and Singapore-based Bio-REV Pte. Ltd.